Feature|Videos|July 18, 2024
The Changing CDMO Landscape: Single-Use Technology, End-to-End Fill Finish Needs and Growth of Cell and Gene
Author(s)AGC Biologics
Key Takeaways
- AGC Biologics’ new fill and finish offering for protein biologics
- Facility expansions and partnerships to address common trends, like the U.S. Biosecure Act
Christoph Winterhalter, Chief Business Officer of AGC Biologics, highlights trends in single-use technology, the CDMO’s new fill-finish capabilities, facility expansions, the potential impact of the U.S. Biosecure Act, and the growing cell and gene market.
Watch this video to learn more:
- AGC Biologics’ new fill and finish offering for protein biologics
- Facility expansions and partnerships to address common trends, like the U.S. Biosecure Act
- The power of single-use technology for developers
- The CDMOs growing cell and gene commercial track record
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
2
Regulatory Challenges for Global Manufacturing of Vaccines
3
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
4
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
5
